EV

Evolent Health, Inc.

EVHHealthcareNASDAQ

Health Information Services · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.88B
-26.6% YoY
Net Income
-$534.5M
-767.4% YoY
EBITDA
-$361.3M
-551.3% YoY
Free Cash Flow
$184.3M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.0082, negative momentum
Aug 27 RSI OverboughtRSI 84.1, above 70, stock may be overbought
About Evolent Health, Inc.

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The $488.4M market capitalization puts EVH squarely in small-cap range for its industry. The company offers integrated value-based care platform for health plan administration and management.

Where EVH stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, EVH finished 11.02% above its 150-day moving average ($3.81) and 9.87% above its 200-day moving average ($3.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is EVH overbought or oversold?

At the September 3, 2026 close, EVH's RSI(14) was 36.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$488.4M
Fwd P/E11.05
EPS$-4.49
Beta0.84
52W Change-56.8%
ROE-67.0%
Analysis

On the balance sheet, EVH has $115.7M in cash with $970.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $184.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -67.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.35B (2022) to $1.88B (2025), reflecting a 39% increase over the period.

Evolent Health, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Evolent Health, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms